Mark R. Szewczak - Concepedia

Author

Mark R. Szewczak

Vion Pharmaceuticals (United States)

Also Known As

M R Szewczak, M Szewczak, M. R. SZEWCZAK, M. R. Szewczak, M. Szewczak, M.R. Szewczak, Mark R. Szewczak

Publications

820

Citations

H-Index

Concepts

All Affiliations

Vion Pharmaceuticals (United States)Somerville Hospital CNS Research (United States)

About

Mark R. Szewczak is an author at Vion Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	343
2	Natural Sciences	2	2	162
3	Social Sciences	2	2	152
4	Biochemistry	2	2	162
5	Chemical Biology	1	1	103

Mark R. Szewczak

Publications

778

Citations

H-Index

Page 1

	Year	Citations
A comparison of clonidine with morphine for antinociceptive and antiwithdrawal actions. Sharmonay Fielding, Jeffrey C. Wilker, Mary Hynes, Journal of Pharmacology and Experimental Therapeutics	1978	225
Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder A. T. WOODS, Craig P. Smith, Mark R. Szewczak, Psychopharmacology Schedule-induced PolydipsiaPsychiatryBehavioral NeuroscienceAddictionPotential Model	1993	132
9-Amino-1,2,3,4-tetrahydroacridin-1-ols. Synthesis and evaluation as potential Alzheimer's disease therapeutics G. M. SHUTSKE, Frank A. Pierrat, Kevin J. Kapples, Journal of Medicinal Chemistry Bioorganic ChemistryNeurotransmitterChemical BiologyPharmaceutical ChemistryMedicinal Chemistry	1989	103
3-[[(Aryloxy)alkyl]piperidinyl]-1,2-Benzisoxazoles as D2/5-HT2 Antagonists with Potential Atypical Antipsychotic Activity: Antipsychotic Profile of Iloperidone (HP 873) Joseph T. Strupczewski, Kenneth J. Bordeau, Yulin Chiang, Journal of Medicinal Chemistry	1995	86
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. Mark R. Szewczak, Roy Corbett, Douglas K. Rush, Journal of Pharmacology and Experimental Therapeutics	1995	60
(.+-.)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity G. M. SHUTSKE, Frank A. Pierrat, Michael L. Cornfeldt, Journal of Medicinal Chemistry Altmetric Attention ScoreNeurochemical BiomarkersPharmacotherapyPre-clinical PharmacologyTranslational Pharmacology	1988	59
Structure−Activity Relationships of a Series of Novel (Piperazinylbutyl)thiazolidinone Antipsychotic Agents Related to 3-[4-[4-(6-Fluorobenzo[<i>b</i>]thien-3-yl)-1-piperazinyl]butyl]-2,5,5-trimethyl-4- thiazolidinone Maleate Nicholas J. Hrib, John G. Jurcak, Deborah E. Bregna, Journal of Medicinal Chemistry	1996	33
Iloperidone: Preclinical Profile and Early Clinical Evaluation Roy Corbett, Lyn R. Griffiths, James E. Shipley, CNS Drug Reviews Translational MedicinePharmacotherapyPreclinical ProfileMedicineSide Effect	1997	29
Besipirdine (HP 749) reduces schedule-induced polydipsia in rats A.T. Woods-Kettleberger, Craig P. Smith, Roy Corbett, Brain Research Bulletin Cardiovascular FunctionPhysiologyHp 749Hypertension	1996	21
Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent: 1. In vivo profile Mark R. Szewczak, Michael L. Cornfeldt, Robert W. Dunn, Drug Development Research Psychotropic MedicationPsychopharmacologyPharmacotherapySocial SciencesMolecular Pharmacology	1987	20

Page 1